Kemp-Harper BK - Search Results

1

Nitroxyl (HNO): the Cinderella of the nitric oxide story.

Irvine JC, Ritchie RH, Favaloro JL, Andrews KL, Widdop RE, Kemp-Harper BK. Irvine JC, et al. Trends Pharmacol Sci. 2008 Dec;29(12):601-8. doi: 10.1016/j.tips.2008.08.005. Epub 2008 Oct 1. Trends Pharmacol Sci. 2008. PMID: 18835046 Review.

2

NO- activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries.

Irvine JC, Favaloro JL, Kemp-Harper BK. Irvine JC, et al. Hypertension. 2003 Jun;41(6):1301-7. doi: 10.1161/01.HYP.0000072010.54901.DE. Epub 2003 May 12. Hypertension. 2003. PMID: 12743008

3

The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature.

Favaloro JL, Kemp-Harper BK. Favaloro JL, et al. Cardiovasc Res. 2007 Feb 1;73(3):587-96. doi: 10.1016/j.cardiores.2006.11.018. Epub 2006 Nov 18. Cardiovasc Res. 2007. PMID: 17189622

4

Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae.

Irvine JC, Favaloro JL, Widdop RE, Kemp-Harper BK. Irvine JC, et al. Hypertension. 2007 Apr;49(4):885-92. doi: 10.1161/01.HYP.0000259328.04159.90. Epub 2007 Feb 19. Hypertension. 2007. PMID: 17309955

5

Redox variants of NO (NO{middle dot} and HNO) elicit vasorelaxation of resistance arteries via distinct mechanisms.

Favaloro JL, Kemp-Harper BK. Favaloro JL, et al. Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1274-80. doi: 10.1152/ajpheart.00008.2009. Epub 2009 Feb 27. Am J Physiol Heart Circ Physiol. 2009. PMID: 19252101 Free article.

6

A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries.

Andrews KL, Irvine JC, Tare M, Apostolopoulos J, Favaloro JL, Triggle CR, Kemp-Harper BK. Andrews KL, et al. Br J Pharmacol. 2009 Jun;157(4):540-50. doi: 10.1111/j.1476-5381.2009.00150.x. Epub 2009 Mar 26. Br J Pharmacol. 2009. PMID: 19338582 Free PMC article.

7

Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond.

Ritchie RH, Irvine JC, Rosenkranz AC, Patel R, Wendt IR, Horowitz JD, Kemp-Harper BK. Ritchie RH, et al. Pharmacol Ther. 2009 Dec;124(3):279-300. doi: 10.1016/j.pharmthera.2009.08.001. Epub 2009 Aug 29. Pharmacol Ther. 2009. PMID: 19723539 Review.

8

Nitroxyl (HNO) as a vasoprotective signaling molecule.

Bullen ML, Miller AA, Andrews KL, Irvine JC, Ritchie RH, Sobey CG, Kemp-Harper BK. Bullen ML, et al. Antioxid Redox Signal. 2011 May 1;14(9):1675-86. doi: 10.1089/ars.2010.3327. Epub 2010 Nov 2. Antioxid Redox Signal. 2011. PMID: 20673125 Review.

9

Chronic administration of the HNO donor Angeli's salt does not lead to tolerance, cross-tolerance, or endothelial dysfunction: comparison with GTN and DEA/NO.

Irvine JC, Kemp-Harper BK, Widdop RE. Irvine JC, et al. Antioxid Redox Signal. 2011 May 1;14(9):1615-24. doi: 10.1089/ars.2010.3269. Epub 2011 Mar 3. Antioxid Redox Signal. 2011. PMID: 20849324

10

Nitroxyl (HNO): a novel redox signaling molecule.

Kemp-Harper BK. Kemp-Harper BK. Antioxid Redox Signal. 2011 May 1;14(9):1609-13. doi: 10.1089/ars.2011.3937. Epub 2011 Mar 8. Antioxid Redox Signal. 2011. PMID: 21299468

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page